3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
2
Neoplasms
2
Motor Activity
2
Thrombocythemia, Essential
1
Rehabilitation Exercise
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Overweight
1
Obesity
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Brain Neoplasms
1
Interventions
selinexor
1
peginterferon alfa-2b
1
Specimen Handling
1
Resistance Training
1
Quality of Life
1
Phlebotomy
1
Observation
1
Maintenance
1
Levofloxacin
1
Exercise
1
Electrocardiography
1
Echocardiography
1
Clinical Laboratory Techniques
1
Busulfan
1
Bone Marrow Examination
1
Biopsy
1
Azacitidine
1
Aspirin
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Myeloproliferative Disorders
×
Resistance Training
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled